When you're a STAT+ subscriber, you get discounts on our STAT Reports and events, free access to premium data tools like our Obesity Drug Tracker, as well as in-depth daily coverage and analysis of the life sciences.
May 16, 2024 | 110 The Embarcadero, San Francisco, CA + Virtual
To a person 20 years ago, today's medicine would seem like science fiction: routine DNA sequencing, gene editing, and surgery that can help an 80-year-old Mick Jagger dance. So what will the next two decades bring? We'll peer into the mists, looking at GLP-1 drugs for psychiatry, a new age of individualized gene editing, and the potential of artificial intelligence to reduce the failure rate of inventing new medicines. We'll also check into the financial apparatus that is supposed to fund all this cool research. Join us for a series of high-level, interactive sessions – and join the conversation.
Save up to 50% through March 3rd with the Early Bird Discount.
March 14, 2024, 1:00 p.m. – 2:00 p.m. EST | Virtual
Several biosimilar versions of Humira, which for years has been the world's best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drug makers are marketing these medicines? Join Pharmalot Columnist and Senior Writer, Ed Silverman, alongside leading experts to discuss the impact of biosimilars on patients and the healthcare industry.
Join STAT Brand Studio for our upcoming virtual event to explore exciting advances in scientific research and why collaboration between industry and academia is more critical than ever. Experts from Astellas Pharma and Mass General Brigham will dive into how building win-win partnerships can accelerate innovation and discuss best practices for building strong foundations to advance tomorrow's groundbreaking therapies.
No comments